Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) that is a critical factor in carcinogenesis, but precise mechanism of its action remains to be elucidated. Here we evaluated the inhibitory effect of celecoxib on cell growth of human oral squamous cell carcinoma (OSCC) YD-10B, which was established to be used as in vitro OSCC model, and identified celecoxib-regulated protein by proteomics techniques. Celecoxib (IC50=37 micrometer) inhibited the growth of YD-10B cells with the decrease of COX-2 protein expression. Its inhibition could be linked in the arrest of G1 phase with increased levels of p(27)protein, a specific CDK inhibitor. Using proteomics, the 10- to 20-fold increase of heterogeneous nuclear ribonuclear protein C (hnRNP C), which has been suggested to be related with the translation of p(27)mRNA, was observed in celecoxib-treated YD-10B cells. In summary, celecoxib has a potential to induce the protein expression of hnRNP C and its increase subsequently induce the translation of p(27)mRNA, which trigger the inhibition of cell growth via p(27)-regulated cell cycle arrest in YD-10B cells. In addition, YD-10B cells could be useful to study the pathological mechanism of OSCC.
Tumor Cells, Cultured ; Tongue Neoplasms/metabolism/pathology ; Sulfonamides/*pharmacology ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Pyrazoles/*pharmacology ; Proteomics/methods ; Male ; Immunoblotting ; Humans ; Heterogeneous-Nuclear Ribonucleoprotein Group C/analysis/*metabolism ; Electrophoresis, Gel, Two-Dimensional ; Cyclooxygenase Inhibitors/pharmacology ; Cyclooxygenase 2/metabolism ; Cyclin-Dependent Kinase Inhibitor p27/analysis/metabolism ; Cell Survival/drug effects ; Cell Proliferation/*drug effects ; Cell Line, Tumor ; Cell Cycle/drug effects ; Carcinoma, Squamous Cell/metabolism/pathology ; Aged ; Actins/metabolism

No abstract available.
Brain* ; Evaluation Studies as Topic* ; Photic Stimulation* ; Tomography, Emission-Computed, Single-Photon*

he purpose of this study was to evaluate the usefulness of whole body F-18 FDG PET scan for deceting postoperative recurrence of cancer. One hundred four cancer patients after operation were enrolled(l4 brain tumor, 15 head and neck cancer, 23 gynecologic cancer). Besides conventional images(CI) including CT and MRI, F-18 FDG PET scan was obtained on ECAT EXACT 47 scanner(Siemens-CTI), beginning 60 minutes after injection of 370MBq(10mCi) of F-18 FDG. Regional scan was also obtained with emission image. Transmission images using Ge-68 were carried out for attenuation correction in both whole body and regional images. Findings of PET and CI were confirmed by pathology or clinical follow up. The sensitivity and specificity of PET for detecting recurrence were 94% and 92%, respectively. Contrarily, the sensitivity and specific it of CI were 78% and 68% CI results were negative and PET results were positive in 11 cases. The biopsy or clinical follow-up of those cases confirmed recurrence of tumor. False negative cases of CI were frequent in patients with gynecologic cancers. Also we measured the Serum concentration of tumor markers in patients with gynecologic cancer(CA125), thyroid cancer(thyroglobulin), and colorectal cancer(CEA). The sensitivity and specificity of tumor markers were 71% and 84%, respectively. We conclude that F-18 FDG PET can be used valuably in detecting recurrent foci of a wide variety of malignancy compared to conventional diagnositic methods.
Biopsy ; Brain Neoplasms ; Follow-Up Studies ; Head and Neck Neoplasms ; Humans ; Magnetic Resonance Imaging ; Pathology ; Positron-Emission Tomography ; Recurrence* ; Sensitivity and Specificity ; Thyroid Gland ; Biomarkers, Tumor

The Harlequin fetus-ichthyosis fetalis-is known to be rare. Recently, we experienced a case of Harlequin fetus in stillborn infant due to autosomal recessive inheritance likely. A review of literature was done briefly.
Humans ; Ichthyosis, Lamellar* ; Infant ; Wills